Over half of Houston business leaders say their company has already enabled AI, blockchain, and extended reality technology. Getty Images

When it comes to enabling new technologies to advance business practices, Houston business leaders are ahead of the curve. According to a new study, the majority of the companies surveyed are already using artificial intelligence, blockchain, and extended reality today.

The global study, Technology Vision 2019, was conducted by Accenture and included surveys from 6,600 business and IT executives around the world, including 100 in Houston. Dallas was the only other Texas market surveyed, along with nine other major United States metros — Atlanta, Boston, Chicago, Detroit, Minneapolis, New York City, San Francisco, Seattle, and Washington D.C.

Of the 100 respondents, 91 said that innovation efforts have accelerated within their organization over the past three years because of new technology, and 80 said that while they feel their employees are digitally savvy, they are "waiting" for the company's technology to catch up. However, when it comes to the need to reskill employees due to emerging tech in the workplace, 47 percent says that need will happen within the next two years.

The survey also focused on three distinct technologies — AI, blockchain, and extended reality, which includes augmented reality, virtual reality, and mixed reality. XR responses indicate that 66 percent of business leaders have already used some sort of version of XR either in one or more of their business units (37 percent) or are piloting the technology (29 percent).

The numbers for adoption for AI is similar, with 65 percent of leaders saying they have introduced AI tech in the workplace already —nearly 2 in 5 have already adopted somewhere within the company, while over 1 in 4 say their company has an AI pilot program.

Blockchain, according to the study, falls further down the spectrum in Houston companies. Only 15 percent of the companies have a pilot program, but 42 percent have blockchain technology already in use in one or more business units — for a total of 57 percent adoption rate.

With 5G on the horizon, almost all respondents — 79 percent — say the technology is going to revolutionize their industry in terms of how they provide products or services to their clients. Almost half said that impact will happen and jobs will be altered within the next three years.

Brian Richards, managing director at Accenture, oversees the company's Houston Innovation Hub. The hub welcomes in business leaders who are utilizing Accenture's services to ideate and then implicate innovative technologies. At a recent panel in the Accenture office, Richards spoke to emerging tech in Houston and said there's been no shortage of leaders wanting to move the needle on new tech.

"I've never seen [corporations] more motivated than they are right now to be able to think differently on how they are able to engage Houston," he said.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”